Physician profile
Eric M Estape
NPI 1275611287
$6,178.73
in general payments reported to CMS, 2019-2025
20 companies · $852 in 2025
The $852 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $834 · 2022: $666 · 2023: $1,186 · 2024: $2,641 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,348 · Travel and Lodging: $1,133 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.31 |
| Travel and Lodging | $1,132.65 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Activ Surgical, INC. | $1,278.58 | 2024 | Activsight |
| Intuitive Surgical, INC. | $1,238.72 | 2021-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $973.74 | 2021-2025 | Jemperli, Zejula |
| Momentis Surgical INC. | $355.40 | 2022-2023 | Anovo Surgical System |
| Conmed Corporation | $328.67 | 2024-2025 | Airseal, Conmed Generators |
| Astellas Pharma US INC | $312.71 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $255.11 | 2023-2025 | Lynparza |
| Eisai INC. | $253.52 | 2023-2025 | |
| Seagen INC. | $239.95 | 2022-2023 | Tivdak |
| Pfizer INC. | $222.47 | 2024-2025 | |
| Abbvie INC. | $220.71 | 2021 | |
| Hologic Sales and Service, LLC | $146.28 | 2023-2025 | Acessa Provu System, Coolseal Generator, Myosure Tissue Removal Device |
| Merck Sharp & Dohme LLC | $119.25 | 2021-2025 | Keytruda, Lynparza |
| Baxter Healthcare | $68.00 | 2022 | |
| Coopersurgical, INC. | $51.89 | 2025 | Ally II Ups |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $27.72 | 2022 | |
| Sumitomo Pharma America, INC. | $24.30 | 2025 | Myfembree |
| Springworks Therapeutics, INC. | $22.49 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $20.49 | 2025 | |
| Solventum Corporation | $18.73 | 2025 | V.A.C. Veraflo Cleanse Choice, Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Estape listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.